Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong

被引：0
|
作者：
Loong, H. H. [1 ]
Wong, C. K. H. [2 ]
Leung, L. K. S. [3 ]
Chan, C. P. K. [4 ]
Chang, A. [5 ]
Gibbs, M. [6 ]
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Novartis Oncol Hong Kong, Med Affairs, Hong Kong, Peoples R China
[5] Novartis Oncol Hong Kong, Market Access, Hong Kong, Peoples R China
[6] Novartis Oncol, Dubai, U Arab Emirates
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
527P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [42] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [43] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [44] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
    Nishio, Makoto
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Solomon, Benjamin J.
    Shaw, Alice T.
    Hashigaki, Satoshi
    Ohki, Emiko
    Usari, Tiziana
    Paolini, Jolanda
    Polli, Anna
    Wilner, Keith D.
    Mok, Tony
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
  • [45] THE MANAGEMENT AND COSTS OF LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN GREECE
    Kousoulakou, H.
    Boukovinas, I
    Georgoulias, V
    Kosmidis, P.
    Koumakis, G.
    Makrantonakis, P.
    Samantas, E.
    Syrigos, K.
    Krikelis, D.
    Markouri, A.
    Geitona, M.
    VALUE IN HEALTH, 2015, 18 (07) : A451 - A451
  • [46] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
    Kang, Jin
    Chen, Hua-Jun
    Zhang, Xu-Chao
    Su, Jian
    Zhou, Qing
    Tu, Hai-Yan
    Wang, Zhen
    Wang, Bin-Chao
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Ding, Yan
    Wu, Xue
    Wang, Mei
    Fu, Jian-Gang
    Yang, Zhenfan
    Zhang, Xian
    Shao, Yang W.
    Wu, Yi-Long
    Yang, Jin-Ji
    THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
  • [47] Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases: A case report
    Zhu, Zhouyu
    Chai, Ying
    MEDICINE, 2017, 96 (45)
  • [48] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
  • [49] Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
    Liu, Maobai
    Zhang, Longfeng
    Huang, Qishu
    Li, Na
    Zheng, Bin
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9195 - 9201
  • [50] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
12345